Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Assets Average for 15 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Assets Average rose 10.76% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 10.76% year-over-year, with the annual reading at $1.4 billion for FY2025, 24.49% up from the prior year.
  • Assets Average hit $1.4 billion in Q4 2025 for Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.4 billion in Q4 2025 to a low of $462.5 million in Q1 2021.
  • Historically, Assets Average has averaged $900.1 million across 5 years, with a median of $843.5 million in 2023.
  • Biggest five-year swings in Assets Average: dropped 1.49% in 2021 and later surged 63.93% in 2022.
  • Year by year, Assets Average stood at $621.0 million in 2021, then rose by 20.7% to $749.6 million in 2022, then rose by 19.69% to $897.2 million in 2023, then surged by 43.33% to $1.3 billion in 2024, then rose by 10.76% to $1.4 billion in 2025.
  • Business Quant data shows Assets Average for ANIP at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.